Pharmaceuticals

TIANYU PHARM

TIANYU PHARM released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 811.67 M, actual EPS CNY 0.1212

TIANYU PHARM released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 774.15 M, actual EPS CNY -0.2611

TIANYU PHARM released FY2025 Annual Earnings on April 23 After-Market (BJT), Actual Revenue CNY 3.061 B (Forecast CNY 3.161 B), Actual EPS CNY 0.41 (Forecast CNY 0.775)

TIANYU PHARM FY2026 Q1 Earnings Release on April 24 After-Market (BJT)

TIANYU PHARM to Release FY2025 Earnings on April 24 After-Market (BJT), Forecast Revenue CNY 3.161 B, EPS CNY 0.775

Tianyu Pharm released FY2025 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 2.287 B, actual EPS CNY 0.6302

Tianyu Pharm released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 719.55 M, actual EPS CNY 0.2002

TIANYU PHARM FY2025 Q3 Earnings Release on October 30, 2025 After-Market (BJT)

TIANYU PHARM released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue CNY 808.11 M, actual EPS CNY 0.1822

TIANYU PHARM released FY2025 Semi-Annual Earnings on August 22 After-Market BJT, actual revenue CNY 1.567 B, actual EPS CNY 0.43

TIANYU PHARM to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Tianyu Co. forecasts a 144.29%-238.25% increase in net profit for the first half of 2025

Tianyu Pharmaceutical Subsidiary Obtains Drug Registration Certificate for Rosuvastatin/Ezetimibe Tablets

Tianyu Pharmaceutical's Controlling Shareholder Plans to Reduce Shareholding up to 3%

Shareholder of Tianyu Co. Plans to Reduce Shares

Tianyu Pharmaceutical's Subsidiary Nodew Pharmaceutical Receives Drug Registration Certificate for Montelukast Sodium Tablets

Tianyu Shares Receives European Certification for Irbesartan Active Pharmaceutical Ingredient

Tianyu Pharmaceutical posts robust growth in 2024 and Q1 2025

Tianyu Pharmaceutical 2025Q1 Exceeding Expectations

TIANYU PHARM released FY2025 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 759.32 M, actual EPS CNY 0.2477

300702

TIANYU PHARM announced that the revenue for the third quarter was 720 million yuan, a year-on-year increase of 7.91%; the net profit was 71.4211 million yuan, a year-on-year increase of 123.90%. The revenue for the first three quarters was 2.287 billion yuan, a year-on-year increase of 18.36%; the net profit was 221 million yuan, a year-on-year increase of 159.57%

Zhitong

TIANYU PHARM: Net profit in the third quarter was 71.4211 million yuan, a year-on-year increase of 123.90%

According to the Zhitong Finance APP, TIANYU PHARM announced that its wholly-owned subsidiary Zhejiang Nuode Pharmaceutical Co., Ltd. (referred to as "Nuode Pharmaceutical") recently received the "Drug Registration Certificate" for Candesartan Cilexetil Tablets issued by the National Medical Products Administration. Candesartan Cilexetil Tablets are indicated for primary hypertension

TIANYU PHARM: Candesartan Cilexetil Tablets have completed drug registration

According to the Zhitong Finance APP, TIANYU PHARM released its semi-annual report for 2025, showing an operating income of 1.567 billion yuan, a year-on-year increase of 23.87%. The net profit attributable to shareholders of the listed company was 150 million yuan, a year-on-year increase of 180.96%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 141 million yuan, a year-on-year increase of 125.11%. The basic earnings per share were 0.43 yuan

TIANYU PHARM released its performance for the first half of the year, with a net profit attributable to the parent company of 150 million yuan, an increase of 180.96%

688356

603538

002826

300255

The A-share chemical pharmaceutical sector continues to rise, with TIBET AIM PHARM hitting the limit up, and TIANYU PHARM, CSBIO, Zhendong Pharmaceutical, Menovo, JENKEM, and GuangShengTang following suit

JENKEM

Menovo

TIBET AIM PHARM

CSBIO

According to reports, recently, TIANYU PHARM signed a cooperation agreement with Heilongjiang Fengyou Biotechnology Development Co., Ltd., and the company obtained exclusive authorization for a series of patents that can be used for the development of psychotropic drugs. The company will utilize these exclusively authorized patents to develop related psychotropic drug products and enter the psychotropic drug field

TIANYU PHARM signed a cooperation agreement with Heilongjiang Fengyou Biotechnology Development Co., Ltd

TIANYU PHARM announced that the company has received the European Pharmacopoeia suitability certification for the active pharmaceutical ingredient Brilinta issued by the European Medicines Agency. The acquisition of this certificate indicates that the active pharmaceutical ingredient meets the quality requirements of the European Pharmacopoeia, allowing it to be sold in the European market and other regulated markets that recognize the CEP certificate, which will have a positive impact on the company's efforts to enrich its product offerings and expand into international markets

TIANYU PHARM: The company's bulk lisinopril raw material has obtained the CEP certificate

On the evening of July 28th, TIANYU PHARM announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., received the European Pharmacopoeia suitability certification for the active pharmaceutical ingredient Sitagliptin Phosphate issued by the European Medicines Agency. Sitagliptin Phosphate is an antidiabetic medication that helps control blood sugar levels and is primarily used for the treatment of type 2 diabetes

TIANYU PHARM: Wholly-owned subsidiary's raw materials obtained CEP certification

TIANYU PHARM expects its net profit attributable to shareholders in the first half of 2025 to be between 130 million yuan and 180 million yuan, a year-on-year increase of 144.29%-238.25%. The net profit after deducting non-recurring gains and losses is expected to be between 121 million yuan and 171 million yuan, a year-on-year increase of 92.79%-172.45%. The company has improved the revenue scale and gross profit growth of its non-sartan active pharmaceutical ingredients and intermediates business, CDMO business, and formulation business through measures such as optimizing product structure, improving market layout, and strengthening cost control

TIANYU PHARM issued a profit forecast, expecting a net profit attributable to the parent company of 130 million to 180 million yuan in the first half of the year, a year-on-year increase of 144.29%-238.25%

According to the Zhitong Finance APP, TIANYU PHARM announced that its wholly-owned subsidiary Zhejiang Nuode Pharmaceutical Co., Ltd. ("Nuode Pharmaceutical") recently received the Drug Registration Certificate for Rosuvastatin and Ezetimibe Tablets (I) issued by the National Medical Products Administration (hereinafter referred to as "National Medical Products Administration"). Rosuvastatin and Ezetimibe Tablets (I) are suitable for hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH)

TIANYU PHARM: Rosuvastatin and Ezetimibe Tablets (I) Obtained Drug Registration Certificate

600521

688166

000963

China Merchants Securities released a research report, pointing out that the trend of Chinese innovative drugs going overseas has emerged, and it continues to be optimistic about the investment value of the pharmaceutical sector in the second half of 2025. It suggests paying attention to individual stock opportunities in the upstream pharmaceutical industry chain, advanced manufacturing, and pharmaceutical consumption fields, including medical devices, services, pharmacies, and traditional Chinese medicine. The report emphasizes the enhancement of global competitiveness of innovative drugs, a significant increase in the number of BD projects, and investors should look for potential overseas targets along the industry trend

huahaipharm

BrightGene

HUADONG MEDICINE

WUXI APPTEC

ApicHope

EVEREST MED

CMSC

SONOSCAPE

Hengrui Pharma

HENGRUI PHARMA

Environment Protection

Staidson BioPharm

WUXI XDC

ZHONGSHENGYAOYE

Starry

Guobang Pharma

AKESO

INNOVENT BIO

JUNSHI BIO

Mindray

3SBIO

PHARMARON

Endovastec

HENLIUS

Salubris

InventisBio

WUXI BIO

ACROBIOSYSTEMS

SYNERGY

SKB BIO

Yinhua CSI Chinese Medicine ETF

JOINN

SINOMED

China Merchants Securities: The trend of innovation going overseas has emerged, and we remain optimistic about opportunities in innovative drugs and pharmaceutical consumption

TIANYU PHARM(300702.SZ)